Table 1 outlines 46 recommendations for conducting conventional EE on PM across 9 key clinical and economic domains, adapted to three genetic test types: (1) screening test for disease risk stratification based on genetic predispositions (eg, hereditary breast and ovarian cancers), (2) diagnostic test for early diagnosis of undetected disease or diagnosis of genetic subtypes among affected population, and (3) pharmacogenomic test for prediction adverse drug reactions, treatment efficacy and/or optimized drug dosage (eg, HLA-B*1502 test). This evidence concerns the gene HLA-B and ovarian carcinoma.